Q3 2026 results
| Metric | Result | Change |
|---|---|---|
| Adjusted admissions (same facility) | 3% growth | Up from 2.3% year-to-date |
| ER visits | 5.1% increase | Versus prior year quarter |
| Medicaid Supplemental Payment incremental net benefit | $50 million | Not stated |
| Capital expenditures | $1.36 billion | Not stated |
| Share repurchases | $3 billion | Not stated |
Guidance and outlook
- The company reaffirmed its estimated guidance ranges through 2026 and expects to be in the upper half of those ranges.
- For 2027, the company anticipates earnings will be generally consistent with 2026.
- Volume growth for 2027 is forecasted to be 2% to 3%.
- The company expects to receive approximately $550 million to $650 million less in Medicaid Supplemental Payment net benefits in 2027.
How management sounded
Positive (+6 on our -10 to +10 scale). Management highlighted 22 consecutive quarters of volume growth and reaffirmed full-year guidance to the upper half of their range, despite ongoing payer mix headwinds. Management sounded more upbeat than on 8% of the 190 calls we cover; most companies sound positive on their own calls, so the comparison says more than the label.
Q&A summary
2027 Outlook and Headwinds
Asked: A.J. Rice (UBS) asked about the magnitude of the exchange headwind and if cost savings would continue.
Answer: Management noted they are in early planning stages but expect resiliency programs to continue generating value and are monitoring exchange enrollment and fourth-quarter performance to refine 2027 expectations.
340B Regulation
Asked: Ann Hynes (Mizuno) asked if the 2027 guidance assumes any benefit from the proposed 340B regulation.
Answer: Management stated they are not sizing the potential benefit publicly yet but view the proposed rule as a positive factor for 2027.
Surgical Volume Trends
Asked: Ben Hendrix (RBC) asked about the surgical backdrop and if pent-up demand could provide upside to the 2% to 3% volume growth forecast.
Answer: Management stated they have not landed on specific surgical components for 2027 yet and are monitoring seasonality in the fourth quarter, noting that diverse service offerings help mitigate specific surgical declines.
Payer Mix and Exchange Impact
Asked: Scott Fidel (Goldman Sachs) asked about the impact of H.R. 1 and potential changes in state applications for Medicaid.
Answer: Management noted that work requirements for able-bodied adults in expansion states could have a modest impact in 2027, though they are not ready to size the earnings impact yet.
What to watch before the next call
- The impact of the health insurance exchange volume decline on payer mix and its effect on 2027 earnings.
- The finalization of the Medicare Opts rule regarding 340B and its potential benefit to the company.
- The implementation of H.R. 1 and its specific impact on Medicaid expansion states.
